https://www.pharmaradar360.com/article/vicapsys-life-sciences-forms-advisory-board-following-stateline-merger-56f7f08bb6f5a3b6PharmaRadar360en2026-09-25T16:02:32.000ZVicapsys Life Sciences Forms Advisory Board Following Stateline Mergerhttps://www.pharmaradar360.com/article/newron-provides-update-on-phase-3-enigma-trs-2-study-fff1b0c9b4486667PharmaRadar360en2026-09-25T15:52:43.000ZNewron Provides Update on Phase 3 ENIGMA-TRS 2 Studyhttps://www.pharmaradar360.com/article/innovation-is-driving-a-new-bull-market-in-biotech-16-ways-to-play-it-from-our-r-f1f9afd0dfc1e9edPharmaRadar360en2026-09-25T15:39:00.000ZInnovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.https://www.pharmaradar360.com/article/faq-what-comes-next-for-the-340b-rebate-pilot-f6900c9fa2358bd2PharmaRadar360en2026-09-25T15:37:01.000ZFAQ: What Comes Next for the 340B Rebate Pilothttps://www.pharmaradar360.com/article/european-commission-approves-nezglyal-for-rare-brain-disease-c2623348facae534PharmaRadar360en2026-09-25T15:30:56.000ZEuropean Commission approves Nezglyal for rare brain diseasehttps://www.pharmaradar360.com/article/un-high-level-meeting-on-pandemic-prevention-preparedness-and-response-b2a1545f834e1570PharmaRadar360en2026-09-25T15:26:46.000ZUN High-Level Meeting on Pandemic Prevention, Preparedness, and Responsehttps://www.pharmaradar360.com/article/lilly-wins-approval-for-once-weekly-insulin-shot-7c44bd319c61a23fPharmaRadar360en2026-09-25T15:26:13.000ZLilly wins approval for once-weekly insulin shothttps://www.pharmaradar360.com/article/b-riley-s-top-biotech-picks-ahead-of-3q26-earnings-season-21f4b57a11c16fa9PharmaRadar360en2026-09-25T15:13:19.000ZB. Riley’s Top Biotech Picks Ahead of 3Q26 Earnings Seasonhttps://www.pharmaradar360.com/article/pharmtech-s-weekly-roundup-september-25-2026-b5fc39bb00930c54PharmaRadar360en2026-09-25T15:11:03.000ZPharmTech’s Weekly Roundup—September 25, 2026https://www.pharmaradar360.com/article/weekly-buzz-meso-lly-anip-win-fda-nod-kala-hcti-sign-loi-imvt-halts-lupus-study-16f5375491039879PharmaRadar360en2026-09-25T14:53:00.000ZWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Studyhttps://www.pharmaradar360.com/article/mfn-drug-pricing-won-t-help-but-competition-will-8f6bd219b441a807PharmaRadar360en2026-09-25T14:45:31.000ZMFN Drug Pricing Won’t Help, But Competition Willhttps://www.pharmaradar360.com/article/fda-commissioner-nominee-heidi-overton-is-ignoring-the-science-on-abortion-drug-1a056e8e92e3362ePharmaRadar360en2026-09-25T14:41:19.000ZFDA commissioner nominee Heidi Overton is ignoring the science on abortion drughttps://www.pharmaradar360.com/article/pneumococcal-vaccination-programmes-for-infants-adults-and-individuals-at-increa-8050db2fd0e7d296PharmaRadar360en2026-09-25T14:39:46.000ZPneumococcal vaccination programmes for infants, adults and individuals at increased clinical riskhttps://www.pharmaradar360.com/article/easy-read-guide-to-the-pneumococcal-vaccine-8c98aa2e7ccf2022PharmaRadar360en2026-09-25T14:39:11.000ZEasy Read guide to the pneumococcal vaccinehttps://www.pharmaradar360.com/article/hiv-action-plan-monitoring-and-evaluation-framework-9cb704956fd8cbf0PharmaRadar360en2026-09-25T14:35:37.000ZHIV Action Plan monitoring and evaluation frameworkhttps://www.pharmaradar360.com/article/china-expands-its-manufacturing-role-for-biopharma-s-new-drugs-061c904da3b0dd6dPharmaRadar360en2026-09-25T14:32:48.000ZChina expands its manufacturing role for biopharma’s new drugshttps://www.pharmaradar360.com/article/movianto-opens-major-pharmaceutical-cold-storage-facility-in-germany-1aeea997cdab52faPharmaRadar360en2026-09-25T14:24:38.000ZMovianto Opens Major Pharmaceutical Cold Storage Facility in Germanyhttps://www.pharmaradar360.com/article/fda-commissioner-pick-pledges-to-follow-statutory-requirements-in-fda-hearing-6bf2c47d70768346PharmaRadar360en2026-09-25T14:15:00.000ZFDA commissioner pick pledges to follow statutory requirements in FDA hearinghttps://www.pharmaradar360.com/article/nanexa-shares-soar-on-1-17-billion-novo-nordisk-deal-for-injection-technology-ca4540a23314bb08PharmaRadar360en2026-09-25T14:14:43.000ZNanexa shares soar on €1.17 billion Novo Nordisk deal for injection technologyhttps://www.pharmaradar360.com/article/adarx-pharmaceuticals-raises-446-million-in-upsized-ipo-e629ef97252c4630PharmaRadar360en2026-09-25T14:07:04.000ZADARx Pharmaceuticals raises $446 million in upsized IPOhttps://www.pharmaradar360.com/article/vicapsys-life-sciences-announces-advisory-board-following-completion-of-statelin-ab434b9c25697d61PharmaRadar360en2026-09-25T14:05:00.000ZVicapsys Life Sciences Announces Advisory Board Following Completion of Stateline Mergerhttps://www.pharmaradar360.com/article/ebitda-per-share-of-teva-pharmaceutical-industries-limited-bsesof-teva-bb0623bc9221f62cPharmaRadar360en2026-09-25T14:04:27.000ZEBITDA per share of Teva Pharmaceutical Industries Limited – BSESOF:TEVAhttps://www.pharmaradar360.com/article/kali-therapeutics-named-to-the-2026-endpoints-11-recognizing-biotech-s-most-prom-74a7f7f08c42a90bPharmaRadar360en2026-09-25T14:01:00.000ZKali Therapeutics Named to the 2026 Endpoints 11, Recognizing Biotech's Most Promising Startupshttps://www.pharmaradar360.com/article/biotech-s-most-exciting-startups-of-2026-meet-this-year-s-endpoints-11-1f64947210f404cePharmaRadar360en2026-09-25T14:00:00.000ZBiotech's most exciting startups of 2026: Meet this year's Endpoints 11https://www.pharmaradar360.com/article/endpoints-news-announces-the-2026-winners-of-the-endpoints-11-awards-showcasing-fc3bb47616ec9a7bPharmaRadar360en2026-09-25T14:00:00.000ZEndpoints News Announces the 2026 Winners of the Endpoints 11 Awards, showcasing biotech’s most exciting startupshttps://www.pharmaradar360.com/article/bristol-myers-squibb-announces-first-presentation-of-results-for-zenbexustm-iber-207c719acf715ab6PharmaRadar360en2026-09-25T14:00:00.000ZBristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/convergesouth-draws-its-largest-crowd-yet-to-winston-salem-with-north-carolina-b-a0deefed0c501d10PharmaRadar360en2026-09-25T13:57:11.000ZConvergeSouth Draws Its Largest Crowd Yet to Winston-Salem, With North Carolina Biotech in the Spotlighthttps://www.pharmaradar360.com/article/longevity-biotech-s-617billion-opportunity-longevity-news-roundup-week-39-2026-a4efa343bee041fcPharmaRadar360en2026-09-25T13:52:59.000ZLongevity Biotech’s $617Billion Opportunity | Longevity News Roundup — Week 39, 2026https://www.pharmaradar360.com/article/ecoceres-supports-astrazeneca-s-net-zero-journey-with-first-hvo-application-in-c-54be299a0feb5eddPharmaRadar360en2026-09-25T13:41:15.000ZEcoCeres supports AstraZeneca’s net-zero journey with first HVO application in China’s pharmaceutical sectorhttps://www.pharmaradar360.com/article/adarx-raises-446m-in-biotech-s-third-largest-ipo-of-2026-city-files-to-go-public-1ed124e1049c5e15PharmaRadar360en2026-09-25T13:39:27.000ZADARx raises $446M in biotech’s third largest IPO of 2026, City files to go publichttps://www.pharmaradar360.com/article/fierce-pharma-asia-lilly-s-3-35b-innocare-deal-korea-s-breakthrough-china-s-5-ye-044c28fe098dc5e6PharmaRadar360en2026-09-25T13:38:04.000ZFierce Pharma Asia—Lilly’s $3.35B InnoCare deal; Korea’s breakthrough; China’s 5-year biotech planhttps://www.pharmaradar360.com/article/kobayashi-in-500-billion-buyout-talks-after-red-yeast-case-415a1d65abcc4062PharmaRadar360en2026-09-25T13:37:35.000ZKobayashi in ¥500 billion buyout talks after red-yeast casehttps://www.pharmaradar360.com/article/is-the-next-generation-of-chinese-biotech-ready-to-go-global-alone-16f3874a1f435179PharmaRadar360en2026-09-25T13:33:44.000ZIs the next generation of Chinese biotech ready to go global alone?https://www.pharmaradar360.com/article/why-retail-pharmacy-s-trust-challenge-is-also-its-path-forward-e2b0702c8d08029bPharmaRadar360en2026-09-25T13:28:02.000ZWhy Retail Pharmacy’s Trust Challenge Is Also Its Path Forwardhttps://www.pharmaradar360.com/article/biotech-pre-market-movers-aiff-jagx-surge-cdt-gctk-slide-d30c867d6ba2929ePharmaRadar360en2026-09-25T13:24:00.000ZBiotech Pre-Market Movers: AIFF, JAGX Surge; CDT, GCTK Slidehttps://www.pharmaradar360.com/article/cphi-milan-usp-benchmarks-reshape-procurement-incentives-1d09ef64bee6e38bPharmaRadar360en2026-09-25T13:15:16.000ZCPHI Milan: USP Benchmarks Reshape Procurement Incentiveshttps://www.pharmaradar360.com/article/movianto-opens-one-of-europe-s-largest-pharmaceutical-logistics-hub-e13951088a73e86fPharmaRadar360en2026-09-25T13:13:51.000ZMovianto opens one of Europe's largest pharmaceutical logistics hubhttps://www.pharmaradar360.com/article/ulefnersen-slows-disease-progression-in-phase-3-als-trial-7764ca56678d1f84PharmaRadar360en2026-09-25T13:11:14.000ZUlefnersen slows disease progression in Phase 3 ALS trialhttps://www.pharmaradar360.com/article/new-graft-versus-host-disease-treatments-what-s-in-the-biotech-pipeline-in-2026-916b9bd374d9f453PharmaRadar360en2026-09-25T13:01:39.000ZNew Graft-versus-Host Disease treatments: What’s in the biotech pipeline in 2026?https://www.pharmaradar360.com/article/italy-s-reported-first-psychedelic-trial-for-hard-to-treat-depression-will-inclu-52166ac52bd4d21fPharmaRadar360en2026-09-25T12:48:00.000ZItaly's reported first psychedelic trial for hard-to-treat depression will include more people.https://www.pharmaradar360.com/article/fda-approves-welireg-and-lenvima-combo-for-advanced-kidney-cancer-004774cf23718913PharmaRadar360en2026-09-25T12:45:00.000ZFDA approves Welireg and Lenvima combo for advanced kidney cancerhttps://www.pharmaradar360.com/article/perma-handtm-silk-suture-bcb56fa36b10c35fPharmaRadar360en2026-09-25T12:00:00.000ZPERMA-HAND™ Silk Suturehttps://www.pharmaradar360.com/article/amplatzertm-amulettm-left-atrial-appendage-occluder-4548369052f42f94PharmaRadar360en2026-09-25T12:00:00.000ZAmplatzer™ Amulet™ Left Atrial Appendage Occluderhttps://www.pharmaradar360.com/article/endpoints-news-hires-reuters-correspondent-maggie-fick-to-cover-u-s-pharma-ac4ed419dd313f6cPharmaRadar360en2026-09-25T11:57:03.000ZEndpoints News Hires Reuters Correspondent Maggie Fick to Cover U.S. Pharmahttps://www.pharmaradar360.com/article/legend-biotech-reports-5-year-carvykti-data-in-myeloma-patients-df8b969fbedfd4abPharmaRadar360en2026-09-25T11:28:49.000ZLegend Biotech reports 5-year CARVYKTI data in myeloma patientshttps://www.pharmaradar360.com/article/legend-biotech-reports-five-year-cartitude-2-data-showing-durable-treatment-free-2cdf62d76e1caf6ePharmaRadar360en2026-09-25T11:11:00.000ZLegend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myelomahttps://www.pharmaradar360.com/article/legend-biotech-presents-carvykti-data-showing-half-of-patients-with-rrmm-remaine-ff4a6ffb89197ecbPharmaRadar360en2026-09-25T11:07:48.000ZLegend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusionhttps://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-phase-3-astra-study-of-aurn001-for-cornea-793eaa6eb89c9b72PharmaRadar360en2026-09-25T11:06:04.000ZAurion Biotech completes enrollment in phase 3 ASTRA study of AURN001 for corneal edema secondary to corneal endothelial dysfunctionhttps://www.pharmaradar360.com/article/the-next-alnylam-rnai-biotech-city-therapeutics-files-for-ipo-48715f4874cf4d45PharmaRadar360en2026-09-25T11:04:00.000ZThe next Alnylam? RNAi biotech City Therapeutics files for IPOhttps://www.pharmaradar360.com/article/fda-commissioner-nominee-affirms-mmr-vaccine-safety-despite-trump-s-claims-e1569d4826e14760PharmaRadar360en2026-09-25T11:01:21.000ZFDA commissioner nominee affirms MMR vaccine safety despite Trump’s claimshttps://www.pharmaradar360.com/article/roche-and-earendil-forge-1-5bn-bispecific-discovery-deal-63a03f3822c118f0PharmaRadar360en2026-09-25T11:01:21.000ZRoche and Earendil forge $1.5bn bispecific discovery dealhttps://www.pharmaradar360.com/article/half-of-20-blood-cancer-patients-were-alive-with-no-cancer-progression-or-furthe-93634d310aa07310PharmaRadar360en2026-09-25T11:00:00.000ZHalf of 20 blood cancer patients were alive, with no cancer progression or further treatment, five years after one infusion.https://www.pharmaradar360.com/article/are-electronic-prescribing-systems-as-safe-as-we-think-12bd8c34773b70f3PharmaRadar360en2026-09-25T10:59:18.000ZAre electronic prescribing systems as safe as we think?https://www.pharmaradar360.com/article/u-s-fda-approves-welireg-belzutifan-plus-lenvima-lenvatinib-for-certain-previous-83acca6a2792462aPharmaRadar360en2026-09-25T10:45:00.000ZU.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)https://www.pharmaradar360.com/article/jusvinza-demonstrates-efficacy-against-chikungunya-f7d6ecb9e836d600PharmaRadar360en2026-09-25T10:43:22.000ZJusvinza Demonstrates Efficacy Against Chikungunyahttps://www.pharmaradar360.com/article/find-product-information-about-medicines-985a650e836aba64PharmaRadar360en2026-09-25T10:32:59.000ZFind product information about medicineshttps://www.pharmaradar360.com/article/novo-does-another-small-deal-this-time-with-drug-delivery-biotech-nanexa-7af623e602aaf0f3PharmaRadar360en2026-09-25T10:29:00.000ZNovo does another small deal, this time with drug delivery biotech Nanexahttps://www.pharmaradar360.com/article/safer-radiotherapy-triannual-event-analysis-and-learning-e491d544e5e562baPharmaRadar360en2026-09-25T10:20:59.000ZSafer radiotherapy: triannual event analysis and learninghttps://www.pharmaradar360.com/article/can-legend-biotech-legn-turn-cell-therapy-scale-into-compounding-wealth-9cd9384b41318f65PharmaRadar360en2026-09-25T10:06:04.000ZCan Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth?https://www.pharmaradar360.com/article/fda-nominee-faces-bipartisan-scrutiny-over-vaccines-and-abortion-drug-981d4c9267bd431fPharmaRadar360en2026-09-25T10:00:00.000ZFDA nominee faces bipartisan scrutiny over vaccines and abortion drughttps://www.pharmaradar360.com/article/dispatches-from-cgt-international-big-pharma-m-a-is-the-new-biotech-ipo-c9b1d472ba4b94cfPharmaRadar360en2026-09-25T09:59:04.000ZDispatches from CGT International: Big pharma M&A is the new biotech IPOhttps://www.pharmaradar360.com/article/phoenix-quad-c-thoma-bravo-target-occupational-health-pharmaceutical-growth-driv-2a771b66ec7f2301PharmaRadar360en2026-09-25T09:38:09.000ZPhoenix, Quad-C, Thoma Bravo target occupational health; Pharmaceutical growth drives May River’s sale of Dickson to Blackstone and Copelandhttps://www.pharmaradar360.com/article/why-biotech-is-becoming-essential-to-the-future-of-food-and-how-ai-is-accelerati-cd444053f8da00cdPharmaRadar360en2026-09-25T08:58:25.000ZWhy biotech is becoming essential to the future of food – and how AI is accelerating the journeyhttps://www.pharmaradar360.com/article/novo-inks-1-3b-nanexa-deal-to-unlock-long-acting-obesity-injectables-a881a2e28ecbc524PharmaRadar360en2026-09-25T08:53:48.000ZNovo inks $1.3B Nanexa deal to unlock long-acting obesity injectableshttps://www.pharmaradar360.com/article/wnt-drug-gives-msd-first-eye-disease-win-after-eyebio-deal-c83e09dee95e6dcfPharmaRadar360en2026-09-25T08:48:21.000ZWnt drug gives MSD first eye disease win after EyeBio dealhttps://www.pharmaradar360.com/article/auburn-native-s-biotech-company-goes-public-it-s-incredibly-rewarding-d118005799e1566dPharmaRadar360en2026-09-25T08:45:00.000ZAuburn native's biotech company goes public: 'It's incredibly rewarding'https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-cdna-13-gral-15-twst-16-adpt-rvty-41820e80afb11d18PharmaRadar360en2026-09-25T08:39:00.000ZBiotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTYhttps://www.pharmaradar360.com/article/trump-pick-to-lead-fda-questioned-by-us-senate-da9afb42dd1ba14bPharmaRadar360en2026-09-25T08:22:00.000ZTrump pick to lead FDA questioned by US Senatehttps://www.pharmaradar360.com/article/msd-s-eye-drug-meets-primary-endpoint-in-trial-de38639efd712b58PharmaRadar360en2026-09-25T08:05:00.000ZMSD’s eye drug meets primary endpoint in trialhttps://www.pharmaradar360.com/article/confirmatory-trials-and-the-new-realities-of-fda-expedited-approval-6cd33a2239afedccPharmaRadar360en2026-09-25T07:57:26.000ZConfirmatory trials and the new realities of FDA expedited approvalhttps://www.pharmaradar360.com/article/atyr-pharma-reaches-fda-protocol-agreement-for-efzofitimod-phase-3-trial-ff90d06e40159c37PharmaRadar360en2026-09-25T07:48:29.000ZaTyr Pharma Reaches FDA Protocol Agreement for Efzofitimod Phase 3 Trialhttps://www.pharmaradar360.com/article/adarx-prices-446-3m-nasdaq-debut-continuing-industry-s-ipo-momentum-bf62d46d4f4c34c2PharmaRadar360en2026-09-25T07:46:00.000ZADARx prices $446.3M Nasdaq debut, continuing industry’s IPO momentumhttps://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875PharmaRadar360en2026-09-25T07:41:25.000ZSLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upsidehttps://www.pharmaradar360.com/article/roche-pays-atavistik-bio-usd-70m-upfront-in-research-partnership-3aae3741cae97a47PharmaRadar360en2026-09-25T07:36:46.000ZRoche pays Atavistik Bio USD 70m upfront in research partnershiphttps://www.pharmaradar360.com/article/kobayashi-in-3-2-billion-buyout-talks-after-red-yeast-case-915308a75717f883PharmaRadar360en2026-09-25T07:34:47.000ZKobayashi in $3.2 Billion Buyout Talks After Red-Yeast Casehttps://www.pharmaradar360.com/article/cryoport-strong-pipeline-of-cell-and-gene-therapy-approvals-nasdaq-cyrx-61f64e59e3b25d5aPharmaRadar360en2026-09-25T07:26:56.000ZCryoport: Strong Pipeline Of Cell And Gene Therapy Approvals (NASDAQ:CYRX)https://www.pharmaradar360.com/article/is-it-smart-to-buy-aska-pharmaceutical-holdings-co-ltd-tse-4886-before-it-goes-e-3f677d584b0cf63bPharmaRadar360en2026-09-25T07:17:18.000ZIs It Smart To Buy ASKA Pharmaceutical Holdings Co.,Ltd. (TSE:4886) Before It Goes Ex-Dividend?https://www.pharmaradar360.com/article/the-pre-cision-platform-wins-research-and-development-achievement-award-from-pha-32dde6afcca1bf48PharmaRadar360en2026-09-25T07:09:46.000ZThe pre|CISION® Platform Wins Research and Development Achievement Award from Pharma Industry Awards UK 2026https://www.pharmaradar360.com/article/black-hawk-locks-in-meteora-financing-for-vesicor-biotech-merger-59ec0fc485d3bbaaPharmaRadar360en2026-09-25T07:04:45.000ZBlack Hawk locks in Meteora financing for Vesicor biotech mergerhttps://www.pharmaradar360.com/article/adarx-scores-upsized-446m-ipo-while-city-maps-out-nasdaq-plans-27b8fac812a355c8PharmaRadar360en2026-09-25T06:46:52.000ZADARx scores upsized $446M IPO, while City maps out Nasdaq planshttps://www.pharmaradar360.com/article/acadia-reports-phase-2-results-for-remlifanserin-in-alzheimer-s-disease-psychosi-c74361f0213b1564PharmaRadar360en2026-09-25T06:43:28.000ZAcadia Reports Phase 2 Results for Remlifanserin in Alzheimer’s Disease Psychosishttps://www.pharmaradar360.com/article/kyverna-reports-one-year-miv-cel-data-in-stiff-person-syndrome-gmg-624d0813a544aea2PharmaRadar360en2026-09-25T06:43:28.000ZKyverna Reports One-Year miv-cel Data in Stiff Person Syndrome, gMGhttps://www.pharmaradar360.com/article/sefaxersen-meets-primary-endpoint-in-phase-3-iga-nephropathy-trial-517888a3e70e4a9cPharmaRadar360en2026-09-25T06:43:28.000ZSefaxersen Meets Primary Endpoint in Phase 3 IgA Nephropathy Trialhttps://www.pharmaradar360.com/article/teclistamab-plus-daratumumab-shows-18-point-survival-gain-at-3-years-in-multiple-5f53bbf58e19036bPharmaRadar360en2026-09-25T06:38:33.000ZTeclistamab plus daratumumab shows 18-point survival gain at 3 years in multiple myelomahttps://www.pharmaradar360.com/article/biotech-us-house-and-senate-propose-2-bills-for-cisa-to-step-up-the-protection-o-75a015ecbb7d07ecPharmaRadar360en2026-09-25T06:23:38.000ZBiotech: US House and Senate propose 2 bills for CISA to step up the protection of biotechnology infrastructurehttps://www.pharmaradar360.com/article/big-read-big-pharma-bets-billions-on-china-biotech-will-washington-pull-the-plug-0756239395352f22PharmaRadar360en2026-09-25T06:19:19.000Z[Big read] Big Pharma bets billions on China biotech — will Washington pull the plug?https://www.pharmaradar360.com/article/big-read-big-pharma-bets-billions-on-china-biotech-will-washington-pull-the-plug-3511dc5fb4bbb15aPharmaRadar360en2026-09-25T06:19:18.000Z[Big read] Big Pharma bets billions on China biotech — will Washington pull the plug?https://www.pharmaradar360.com/article/the-focus-01-clinical-trial-design-and-preclinical-data-further-demonstrate-the-0802ba0230a00153PharmaRadar360en2026-09-25T06:01:23.000ZThe FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancerhttps://www.pharmaradar360.com/article/santen-pharmaceutical-tse-4536-could-be-a-buy-for-its-upcoming-dividend-211ec25c526845c1PharmaRadar360en2026-09-25T05:59:24.000ZSanten Pharmaceutical (TSE:4536) Could Be A Buy For Its Upcoming Dividendhttps://www.pharmaradar360.com/article/why-it-might-not-make-sense-to-buy-kyorin-pharmaceutical-co-ltd-tse-4569-for-its-b0042c5cef02d226PharmaRadar360en2026-09-25T05:50:54.000ZWhy It Might Not Make Sense To Buy KYORIN Pharmaceutical Co., Ltd. (TSE:4569) For Its Upcoming Dividendhttps://www.pharmaradar360.com/article/health-brief-the-tightrope-faced-by-trump-s-fda-pick-5298af1eb3d49489PharmaRadar360en2026-09-25T04:34:24.000ZHealth Brief: The tightrope faced by Trump’s FDA pickhttps://www.pharmaradar360.com/article/movianto-opens-30-000-sqm-pharmaceutical-logistics-hub-in-germany-06c67aeac3bd7d82PharmaRadar360en2026-09-25T04:00:39.000ZMovianto opens 30,000-sqm pharmaceutical logistics hub in Germanyhttps://www.pharmaradar360.com/article/mrna-on-track-to-be-september-s-no-2-s-p-500-stock-but-these-5-smaller-health-ca-c11e7e5386621baaPharmaRadar360en2026-09-25T03:23:00.000ZMRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Betterhttps://www.pharmaradar360.com/article/sunhawk-vision-biotech-inc-cash-flow-tpex-7759-7c6d9d5bf85008f9PharmaRadar360en2026-09-25T02:21:46.000ZSunhawk Vision Biotech, Inc. Cash Flow – TPEX:7759https://www.pharmaradar360.com/article/young-discusses-american-biotech-leadership-at-axios-live-event-7d6d523c5d4a26a9PharmaRadar360en2026-09-25T01:26:29.000ZYoung Discusses American Biotech Leadership at Axios Live Eventhttps://www.pharmaradar360.com/article/adrx-ipo-news-sirna-biotech-adarx-pharmaceuticals-prices-upsized-ipo-at-17-the-h-b33fc17edd8dc0b6PharmaRadar360en2026-09-25T00:53:00.000ZADRX IPO News - siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the rangehttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-advances-oncology-pipeline-as-xlife-sciences-reports-first-h-4e1dcb90c50a16abPharmaRadar360en2026-09-25T00:40:35.000ZVERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progresshttps://www.pharmaradar360.com/article/rnai-drug-specialist-adarx-raises-446m-ipo-bbfd6fd6937188fbPharmaRadar360en2026-09-25T00:37:33.000ZRNAi drug specialist ADARx raises $446M IPOhttps://www.pharmaradar360.com/article/otsuka-foods-to-revise-prices-of-some-products-new-prices-to-take-effect-with-de-dae178c5cb3b056cPharmaRadar360en2026-09-25T00:00:00.000ZOtsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of January 1, 2027https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-03aa51ad112ed187PharmaRadar360en2026-09-25T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-a3c60eda2caaecc9PharmaRadar360en2026-09-25T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-a905c0921f2cef9cPharmaRadar360en2026-09-25T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-78b9f3ef148dda6bPharmaRadar360en2026-09-25T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-8fe24b449636c1c4PharmaRadar360en2026-09-25T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-6216d8c58bd0d300PharmaRadar360en2026-09-25T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-1062070d6eb6a85bPharmaRadar360en2026-09-25T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-6b4c64368e1fec16PharmaRadar360en2026-09-25T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-c1c54265c51cdc73PharmaRadar360en2026-09-25T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-0ffaca167a875c5bPharmaRadar360en2026-09-25T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-14c995e3ffd2210dPharmaRadar360en2026-09-25T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-713eb6aae0fa7c4ePharmaRadar360en2026-09-25T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-8813eee8b06bb8b5PharmaRadar360en2026-09-25T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-218f9fbd940e9298PharmaRadar360en2026-09-25T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicaid-and-children-s-health-insurance-program-chip-generic-information-collec-a517ce386e9bcc9aPharmaRadar360en2026-09-25T00:00:00.000ZMedicaid and Children's Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/draft-nih-policy-on-sharing-summary-level-study-results-with-clinical-research-p-91eacb94fe96ce62PharmaRadar360en2026-09-25T00:00:00.000ZDraft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participantshttps://www.pharmaradar360.com/article/robotically-assisted-surgical-devices-premarket-submissions-draft-guidance-for-i-f617f9d98de05341PharmaRadar360en2026-09-25T00:00:00.000ZRobotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availabilityhttps://www.pharmaradar360.com/article/dermatologic-and-ophthalmic-drugs-advisory-committee-notice-of-meeting-establish-e70cef7ecba8973bPharmaRadar360en2026-09-25T00:00:00.000ZDermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%https://www.pharmaradar360.com/article/reauthorization-of-the-biosimilar-user-fee-act-public-meeting-request-for-commen-e1de7e5e0a4360e9PharmaRadar360en2026-09-25T00:00:00.000ZReauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Commentshttps://www.pharmaradar360.com/article/filing-of-color-additive-petition-from-doehler-gmbh-request-to-amend-the-color-a-fa83a20668624e42PharmaRadar360en2026-09-25T00:00:00.000ZFiling of Color Additive Petition From Doehler GmbH; Request To Amend the Color Additive Regulations To Provide for the Safe Use of Calcium Sulfate in Various Foods at Levels Consistent With Good Manufacturing Practicehttps://www.pharmaradar360.com/article/food-additives-permitted-for-direct-addition-to-food-for-human-consumption-vitam-4f95d0d5dc7d090ePharmaRadar360en2026-09-25T00:00:00.000ZFood Additives Permitted for Direct Addition to Food for Human Consumption; Vitamin D2 Inactive Bakers Yeasthttps://www.pharmaradar360.com/article/jeffrey-thies-final-debarment-order-3892b6ffea2019a7PharmaRadar360en2026-09-25T00:00:00.000ZJeffrey Thies: Final Debarment Orderhttps://www.pharmaradar360.com/article/naveed-aslam-final-debarment-order-93b24598baec685ePharmaRadar360en2026-09-25T00:00:00.000ZNaveed Aslam: Final Debarment Orderhttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-77516d93d671562ePharmaRadar360en2026-09-25T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/six-cleveland-clinic-hospitals-recognized-as-top-performers-by-vizient-0f6d6d965abc6e20PharmaRadar360en2026-09-25T00:00:00.000ZSix Cleveland Clinic Hospitals Recognized as Top Performers by Vizienthttps://www.pharmaradar360.com/article/retained-root-fragments-following-exodontia-a-narrative-review-of-clinical-outco-9379bf909d7708cdPharmaRadar360en2026-09-25T00:00:00.000ZRetained Root Fragments Following Exodontia: A Narrative Review of Clinical outcomes, Risk-Based Management, and the Ethico-Legal Standard of Disclosurehttps://www.pharmaradar360.com/article/debriefing-characteristics-associated-with-the-development-of-clinical-judgment-52584a8e15933521PharmaRadar360en2026-09-25T00:00:00.000ZDebriefing Characteristics Associated With the Development of Clinical Judgment in Nursing Studentshttps://www.pharmaradar360.com/article/precision-periodontology-promise-practicality-and-clinical-reality-1e0dfc4f5dbe38f0PharmaRadar360en2026-09-25T00:00:00.000ZPrecision Periodontology: Promise, Practicality and Clinical Realityhttps://www.pharmaradar360.com/article/predictive-factors-for-hemoglobin-decrease-after-simple-open-prostatectomy-singl-5786a2682345ae91PharmaRadar360en2026-09-25T00:00:00.000ZPredictive Factors for Hemoglobin Decrease After Simple Open Prostatectomy: Single-center Clinical Experiencehttps://www.pharmaradar360.com/article/understanding-gender-dysphoria-through-diverse-clinical-presentations-6af452b0df960475PharmaRadar360en2026-09-25T00:00:00.000ZUnderstanding gender dysphoria through diverse clinical presentationshttps://www.pharmaradar360.com/article/effectiveness-and-safety-of-ultrasound-guided-quadratus-lumborum-block-combined-31384ddc215f7dd5PharmaRadar360en2026-09-25T00:00:00.000ZEffectiveness and safety of ultrasound-guided quadratus lumborum block combined with low-dose spinal anesthesia &lt;i&gt;versus&lt;/i&gt; general anesthesia in percutaneous nephrolithotomy: a randomized controlled trialhttps://www.pharmaradar360.com/article/the-social-architecture-of-participation-7b1cd5b917b0f0daPharmaRadar360en2026-09-25T00:00:00.000ZThe Social Architecture of Participationhttps://www.pharmaradar360.com/article/targeting-a-moving-threshold-antigen-density-as-a-design-constraint-for-particul-fe54455bb8a0b1f9PharmaRadar360en2026-09-25T00:00:00.000ZTargeting a Moving Threshold: Antigen Density as a Design Constraint for Particulate Drug Delivery in HER2-Low and HER2-Ultralow Breast Cancer—A Narrative Reviewhttps://www.pharmaradar360.com/article/the-challenge-of-treating-syringomyelia-associated-with-extensive-arachnoiditis-74de3063e7988678PharmaRadar360en2026-09-25T00:00:00.000ZThe Challenge of Treating Syringomyelia Associated with Extensive Arachnoiditishttps://www.pharmaradar360.com/article/nod2-variants-and-duration-of-hospitalization-after-endoscopic-treatment-of-bili-fff75a7aa65897ebPharmaRadar360en2026-09-25T00:00:00.000ZNOD2 Variants and Duration of Hospitalization After Endoscopic Treatment of Biliary Strictures Following Liver Transplantation: A Cutoff-Dependent Associationhttps://www.pharmaradar360.com/article/dynamic-changes-in-serum-neutrophil-gelatinase-associated-lipocalin-for-discrimi-82b06f23ed85e2efPharmaRadar360en2026-09-25T00:00:00.000ZDynamic Changes in Serum Neutrophil Gelatinase-Associated Lipocalin for Discrimination of Creatinine-Defined Acute Kidney Injury After Laparoscopic Sleeve Gastrectomy: A Prospective Observational Cohort Studyhttps://www.pharmaradar360.com/article/retrospective-assessment-of-llm-decision-making-for-iol-power-selection-in-catar-8e2149ab35ed73e5PharmaRadar360en2026-09-25T00:00:00.000ZRetrospective Assessment of LLM Decision-Making for IOL Power Selection in Cataract Surgery in Comparison with Surgeon Performancehttps://www.pharmaradar360.com/article/multimodality-imaging-of-mitral-regurgitation-2f6766a1086173c4PharmaRadar360en2026-09-25T00:00:00.000ZMultimodality Imaging of Mitral Regurgitationhttps://www.pharmaradar360.com/article/bullying-and-cyberbullying-in-childhood-and-adolescence-a-narrative-review-and-p-76e3cd8ef6e55b2ePharmaRadar360en2026-09-25T00:00:00.000ZBullying and Cyberbullying in Childhood and Adolescence: A Narrative Review and Proposed Clinical Response Frameworkhttps://www.pharmaradar360.com/article/validation-of-the-hungarian-fad-gf-and-baffs-in-a-multi-informant-clinical-sampl-3fe5b25c797bd30dPharmaRadar360en2026-09-25T00:00:00.000ZValidation of the Hungarian FAD-GF and BAFFS in a Multi-Informant Clinical Sample of Families of Adolescentshttps://www.pharmaradar360.com/article/vermicomposting-reshapes-microbial-communities-and-functional-potential-in-sewag-ae6e64b6b8199af4PharmaRadar360en2026-09-25T00:00:00.000ZVermicomposting Reshapes Microbial Communities and Functional Potential in Sewage Sludge: Insights from 16S and ITS Metabarcodinghttps://www.pharmaradar360.com/article/choriocapillaris-dysfunction-in-retinal-diseases-multimodal-imaging-biomarkers-p-4b51271ff5f4702bPharmaRadar360en2026-09-25T00:00:00.000ZChoriocapillaris Dysfunction in Retinal Diseases: Multimodal Imaging Biomarkers, Pathophysiological Insights, and Emerging Clinical Applicationshttps://www.pharmaradar360.com/article/phenotypic-divergence-among-genomically-closely-related-klebsiella-pneumoniae-cl-d785ff96c21dac46PharmaRadar360en2026-09-25T00:00:00.000ZPhenotypic Divergence Among Genomically Closely Related Klebsiella pneumoniae Clinical Isolateshttps://www.pharmaradar360.com/article/feasibility-of-a-teacher-supervised-chatgpt-assisted-workflow-for-individualized-3e57e1bd3fbefb65PharmaRadar360en2026-09-25T00:00:00.000ZFeasibility of a teacher-supervised ChatGPT-assisted workflow for individualized exercise planning in university physical education: a two-phase study using a fuzzy Delphi process and a cluster pilot trialhttps://www.pharmaradar360.com/article/correction-clinical-relevance-of-loneliness-in-the-treatment-of-depression-study-488121acc67451a2PharmaRadar360en2026-09-25T00:00:00.000ZCorrection: Clinical relevance of loneliness in the treatment of depression: study protocol for a naturalistic prospective longitudinal studyhttps://www.pharmaradar360.com/article/added-effects-of-dual-task-water-based-exercise-on-global-cognition-and-physical-d78831b4678fef85PharmaRadar360en2026-09-25T00:00:00.000ZAdded effects of dual-task water-based exercise on global cognition and physical performance in older women: a three-arm randomized controlled trialhttps://www.pharmaradar360.com/article/cannabinoids-in-hematologic-malignancies-mechanisms-and-therapeutic-potential-fo-455ec19e5f96dc3dPharmaRadar360en2026-09-25T00:00:00.000ZCannabinoids in hematologic malignancies: mechanisms and therapeutic potential for overcoming drug resistancehttps://www.pharmaradar360.com/article/real-world-clinical-outcomes-and-safety-of-anlotinib-containing-regimens-in-pedi-730b69bf7352220bPharmaRadar360en2026-09-25T00:00:00.000ZReal-world clinical outcomes and safety of anlotinib-containing regimens in pediatric solid tumors: a retrospective cohort study at a Chinese centerhttps://www.pharmaradar360.com/article/transcutaneous-auricular-vagus-nerve-stimulation-tavns-a-comprehensive-review-of-3a56ae80f15917b1PharmaRadar360en2026-09-25T00:00:00.000ZTranscutaneous auricular vagus nerve stimulation (taVNS): a comprehensive review of mechanisms, clinical applications, and future directionshttps://www.pharmaradar360.com/article/effects-of-12-week-24-form-tai-chi-on-cognitive-function-cerebral-perfusion-and-3074684e688c186cPharmaRadar360en2026-09-25T00:00:00.000ZEffects of 12-week 24-form Tai Chi on cognitive function, cerebral perfusion, and vascular function in postmenopausal women with mild cognitive impairment: an exploratory randomized controlled trialhttps://www.pharmaradar360.com/article/delayed-diagnosis-of-selected-thoracic-and-mediastinal-conditions-in-young-adult-8b5dc28ca3ef2176PharmaRadar360en2026-09-25T00:00:00.000ZDelayed diagnosis of selected thoracic and mediastinal conditions in young adults: a focused narrative review of clinical pitfalls, cognitive biases, and system barriershttps://www.pharmaradar360.com/article/editorial-new-concepts-advances-and-future-trends-in-clinical-research-on-eye-di-a57c8623c59995e7PharmaRadar360en2026-09-25T00:00:00.000ZEditorial: New concepts, advances, and future trends in clinical research on eye diseaseshttps://www.pharmaradar360.com/article/clinical-manifestations-and-proportions-of-severe-outcomes-in-pediatric-acute-po-554128e88e8ff456PharmaRadar360en2026-09-25T00:00:00.000ZClinical manifestations and proportions of severe outcomes in pediatric acute post-streptococcal glomerulonephritis: a systematic review and meta-analysis of predominantly hospital-based cohortshttps://www.pharmaradar360.com/article/deproteinized-calf-blood-extract-with-or-without-punctal-plugs-versus-preservati-8d74bf281ef03d4bPharmaRadar360en2026-09-25T00:00:00.000ZDeproteinized calf blood extract With or without punctal plugs versus preservative-free sodium hyaluronate for glaucoma-associated ocular surface disease: a three-arm randomized controlled trialhttps://www.pharmaradar360.com/article/omentin-1-and-cardiovascular-disease-a-comprehensive-review-from-molecular-mecha-8982c91fdb3fc976PharmaRadar360en2026-09-25T00:00:00.000ZOmentin-1 and cardiovascular disease: a comprehensive review from molecular mechanisms to clinical translationhttps://www.pharmaradar360.com/article/clinical-characteristics-and-genotype-phenotype-correlation-analysis-in-279-pati-32e62f97fa08d151PharmaRadar360en2026-09-25T00:00:00.000ZClinical characteristics and genotype–phenotype correlation analysis in 279 patients with 5α-reductase type 2 deficiencyhttps://www.pharmaradar360.com/article/a-pre-market-open-label-single-arm-study-to-evaluate-b-bone-for-posterolateral-f-fd21f5760f204dbaPharmaRadar360en2026-09-25T00:00:00.000ZA pre-market, open-label, single-arm study to evaluate b.Bone for posterolateral fusion treatment of degenerative thoracolumbar, lumbar or lumbosacral spinal disease (b.Spine clinical trial)https://www.pharmaradar360.com/article/author-s-response-to-the-comments-on-long-term-clinical-and-functional-outcomes-344b23c04227b021PharmaRadar360en2026-09-25T00:00:00.000ZAuthor’s response to the Comments on: “Long-term clinical and functional outcomes of ultrasound-guided platelet-rich plasma injection for long head of the biceps tendinopathy: A prospective study”https://www.pharmaradar360.com/article/protein-drug-interaction-in-psoriasis-therapy-using-molecular-docking-and-molecu-8ace86625ddb7a15PharmaRadar360en2026-09-25T00:00:00.000ZPROTEIN-DRUG INTERACTION IN PSORIASIS THERAPY USING MOLECULAR DOCKING AND MOLECULAR DYNAMICS MODELINGhttps://www.pharmaradar360.com/article/effects-of-nurse-led-care-plan-and-parents-education-on-sleep-quality-and-behavi-c248428cdfe9a25aPharmaRadar360en2026-09-25T00:00:00.000ZEFFECTS OF NURSE-LED CARE PLAN AND PARENTS’ EDUCATION ON SLEEP QUALITY AND BEHAVIOR MODIFICATION IN PEDIATRIC PATIENTShttps://www.pharmaradar360.com/article/explainable-deep-learning-based-integration-of-multi-omics-data-rna-seq-dna-meth-4cf7874d8e5b91afPharmaRadar360en2026-09-25T00:00:00.000ZExplainable Deep Learning-Based Integration of Multi-Omics Data (RNA-Seq, DNA Methylation, and Mutation Profiles) for Predicting Chemotherapy Response and Identifying Key Biomarkers in Breast Cancer: A Reproducible Computational Framework and Demonstration Studyhttps://www.pharmaradar360.com/article/characterization-of-human-mesenchymal-stem-cell-according-to-delivery-route-and-966a5a72762014a4PharmaRadar360en2026-09-25T00:00:00.000ZCharacterization of human mesenchymal stem cell according to delivery route and its correlation with clinical-gynecological historyhttps://www.pharmaradar360.com/article/the-relationship-between-systemic-inflammation-response-index-and-clinical-and-h-cc45a3ab13df34bfPharmaRadar360en2026-09-25T00:00:00.000ZThe relationship between systemic inflammation response index and clinical and histopathological features in gastric cancerhttps://www.pharmaradar360.com/article/predicted-but-powerless-rethinking-clinical-predictors-against-patient-reported-77f69db8b6c5683dPharmaRadar360en2026-09-25T00:00:00.000ZPredicted but Powerless: Rethinking Clinical Predictors Against Patient-reported Recovery in Hospitalized Type 2 Diabeteshttps://www.pharmaradar360.com/article/quantifying-data-leakage-in-multimodal-clinical-augmentation-a-decomposition-fra-8482fc036ca2b068PharmaRadar360en2026-09-25T00:00:00.000ZQuantifying Data Leakage in Multimodal Clinical Augmentation: A Decomposition Framework and a Leakage-Free Evaluation Protocol for Parkinson's Disease Classificationhttps://www.pharmaradar360.com/article/demographic-and-clinical-profile-of-visits-to-the-pediatric-emergency-department-07b84b023040b184PharmaRadar360en2026-09-25T00:00:00.000ZDemographic and Clinical Profile of Visits to the Pediatric Emergency Department of a State Hospital: A 5-Year Retrospective Studyhttps://www.pharmaradar360.com/article/renal-denervation-for-hypertension-mechanisms-evidence-and-clinical-integration-89333ab93d31de1bPharmaRadar360en2026-09-25T00:00:00.000ZRenal Denervation for Hypertension ― Mechanisms, Evidence, and Clinical Integration ―https://www.pharmaradar360.com/article/an-lt-i-gt-in-vivo-lt-i-gt-factor-connecting-sustained-reactive-oxygen-species-c-19516830e05a44b5PharmaRadar360en2026-09-25T00:00:00.000ZAn &lt;i&gt;in Vivo&lt;/i&gt; Factor Connecting Sustained Reactive Oxygen Species Capture with Rapid Disposition: Quercetin Distribution into Hemoglobinhttps://www.pharmaradar360.com/article/exploring-the-impact-of-recipe-boxes-on-dietary-quality-and-food-agency-a-pilot-e1f30ebf291262adPharmaRadar360en2026-09-25T00:00:00.000ZExploring the impact of recipe boxes on dietary quality and food agency: a pilot and feasibility randomized controlled trial in households with school-aged childrenhttps://www.pharmaradar360.com/article/association-of-older-age-and-lower-body-mass-index-with-initial-teicoplanin-trou-8d0a8a8bd7f44a2ePharmaRadar360en2026-09-25T00:00:00.000ZAssociation of older age and lower body mass index with initial teicoplanin trough concentrations: a single-center retrospective cohort studyhttps://www.pharmaradar360.com/article/methods-for-assessing-the-acquisition-of-pharmaceutical-care-skills-among-studen-593bf59c0bc1f1d8PharmaRadar360en2026-09-25T00:00:00.000ZMethods for assessing the acquisition of pharmaceutical care skills among students and pharmacists: a scoping reviewhttps://www.pharmaradar360.com/article/clinical-value-of-targeted-next-generation-sequencing-and-metagenomic-next-gener-0874c5f449175572PharmaRadar360en2026-09-25T00:00:00.000ZClinical value of targeted next-generation sequencing and metagenomic next-generation sequencing in the diagnosis of pulmonary tuberculosis: a real-world propensity score matching studyhttps://www.pharmaradar360.com/article/fully-automated-deep-learning-based-lenke-classification-for-adolescent-idiopath-daf8de2070c9d732PharmaRadar360en2026-09-25T00:00:00.000ZFully Automated Deep Learning-Based Lenke Classification for Adolescent Idiopathic Scoliosis Using Multi-View Full-Spine Radiographs: Development and Clinical Validationhttps://www.pharmaradar360.com/article/navigating-clozapine-discontinuation-in-clinical-practice-an-updated-framework-7488313ea3f6a362PharmaRadar360en2026-09-25T00:00:00.000ZNavigating clozapine discontinuation in clinical practice: An updated frameworkhttps://www.pharmaradar360.com/article/socio-behavioral-research-experiences-and-acceptability-of-serial-lymph-node-and-5062a19f2f415ef6PharmaRadar360en2026-09-25T00:00:00.000ZSocio-Behavioral Research Experiences and Acceptability of Serial Lymph Node and Gut Biopsies Among Young Women Enrolled in an HIV Cure–Related Trial in Durban, South Africahttps://www.pharmaradar360.com/article/ketamine-enhanced-psychotherapy-for-smoking-cessation-a-pilot-study-of-feasibili-018ff76e8825fb30PharmaRadar360en2026-09-25T00:00:00.000ZKetamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomeshttps://www.pharmaradar360.com/article/figure-2-from-shiva02-trial-using-patients-as-their-own-controls-to-assess-effic-6668e28e9218790ePharmaRadar360en2026-09-25T00:00:00.000ZFigure 2 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancerhttps://www.pharmaradar360.com/article/figure-3-from-shiva02-trial-using-patients-as-their-own-controls-to-assess-effic-364f83e96d41bc6cPharmaRadar360en2026-09-25T00:00:00.000ZFigure 3 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancerhttps://www.pharmaradar360.com/article/table-1-from-shiva02-trial-using-patients-as-their-own-controls-to-assess-effica-74b4363d0bc703b3PharmaRadar360en2026-09-25T00:00:00.000ZTable 1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancerhttps://www.pharmaradar360.com/article/beyond-major-pathologic-response-in-lung-cancer-biomarkers-predict-outcomes-2c644ad99e830c5ePharmaRadar360en2026-09-25T00:00:00.000ZBeyond Major Pathologic Response in Lung Cancer: Biomarkers Predict Outcomeshttps://www.pharmaradar360.com/article/galleri-cancer-test-fails-to-meet-main-aim-in-nhs-trial-but-fda-still-endorses-i-a4607d427d15019cPharmaRadar360en2026-09-25T00:00:00.000ZGalleri cancer test fails to meet main aim in NHS trial, but FDA still endorses ithttps://www.pharmaradar360.com/article/effect-of-preoperative-intravenous-crystalloid-bolus-on-postinduction-blood-pres-0ab3a25007a12a6cPharmaRadar360en2026-09-25T00:00:00.000ZEffect of Preoperative Intravenous Crystalloid Bolus on Postinduction Blood Pressure: A Randomized Blinded Intervention Trialhttps://www.pharmaradar360.com/article/is-exercise-effective-at-reducing-pain-catastrophizing-in-people-with-chronic-no-9f4e6c1fe9682df4PharmaRadar360en2026-09-25T00:00:00.000ZIs Exercise Effective at Reducing Pain Catastrophizing in People with Chronic Non-Specific Spinal Pain? A Systematic Review and Meta-analysishttps://www.pharmaradar360.com/article/clinical-outcomes-of-a-3-day-benzodiazepine-detoxification-protocol-with-continu-7896503f860a0cbcPharmaRadar360en2026-09-25T00:00:00.000ZClinical Outcomes of a 3-day Benzodiazepine Detoxification Protocol With Continuous Subcutaneous Flumazenil Infusion: An Open-label Pilot Studyhttps://www.pharmaradar360.com/article/remnant-cholesterol-and-cardiovascular-risk-in-maintenance-haemodialysis-55c8fd1757e06d30PharmaRadar360en2026-09-25T00:00:00.000ZRemnant cholesterol and cardiovascular risk in maintenance haemodialysishttps://www.pharmaradar360.com/article/hyperhomocysteine-a-key-mediator-linking-chronic-kidney-disease-to-parkinson-s-d-4a4fda6ba17b205bPharmaRadar360en2026-09-25T00:00:00.000ZHyperhomocysteine: a key mediator linking chronic kidney disease to parkinson’s diseasehttps://www.pharmaradar360.com/article/clinical-and-scintigraphic-improvement-of-mandibular-involvement-associated-with-863d1e03d48f7f8dPharmaRadar360en2026-09-25T00:00:00.000ZClinical and scintigraphic improvement of mandibular involvement associated with chronic nonbacterial osteitis following an interleukin-23 inhibitor: a case-based literature reviewhttps://www.pharmaradar360.com/article/agreement-between-lunar-densitometers-in-the-capital-region-of-denmark-a-phantom-55a77cdddb8ea4ffPharmaRadar360en2026-09-25T00:00:00.000ZAgreement between lunar densitometers in the capital region of Denmark—a phantom studyhttps://www.pharmaradar360.com/article/clinical-characteristics-of-asymmetric-hearing-loss-in-children-from-a-large-ped-af05d1ae7aef697dPharmaRadar360en2026-09-25T00:00:00.000ZClinical characteristics of asymmetric hearing loss in children from a large pediatric cohorthttps://www.pharmaradar360.com/article/combined-ethanol-and-lauromacrogol-sclerotherapy-for-ovarian-endometriotic-cysts-9cd9b1be8d8f1ac3PharmaRadar360en2026-09-25T00:00:00.000ZCombined ethanol and lauromacrogol sclerotherapy for ovarian endometriotic cysts: a retrospective clinical and experimental studyhttps://www.pharmaradar360.com/article/mass-test-and-treat-mtat-for-malaria-prevalence-in-a-moderate-transmission-setti-0795b638aa2a9426PharmaRadar360en2026-09-25T00:00:00.000ZMass test and treat (MTaT) for malaria prevalence in a moderate transmission setting, a quasi-experimental trial from rural Ghanahttps://www.pharmaradar360.com/article/does-expansion-of-clinical-trial-capacity-improve-healthcare-access-ae0f4d61286726a6PharmaRadar360en2026-09-25T00:00:00.000ZDoes expansion of clinical trial capacity improve healthcare access?https://www.pharmaradar360.com/article/from-n-of-1-therapy-to-health-system-implementation-270f1daf4b4e659cPharmaRadar360en2026-09-25T00:00:00.000ZFrom N-of-1 therapy to health-system implementationhttps://www.pharmaradar360.com/article/drug-discovery-in-india-9d724a6f7997a1e5PharmaRadar360en2026-09-25T00:00:00.000ZDrug Discovery in Indiahttps://www.pharmaradar360.com/article/a-comprehensive-review-of-the-multifaceted-contributions-of-nanoparticles-and-th-91393b62f456a422PharmaRadar360en2026-09-25T00:00:00.000ZA comprehensive review of the multifaceted contributions of nanoparticles and their roles in revolutionizing clinical hepatology, oncology, and virology researchhttps://www.pharmaradar360.com/article/polypharmacy-and-multimorbidity-in-hospitalized-patients-clinical-consequences-a-98df5e6edbb17c16PharmaRadar360en2026-09-25T00:00:00.000ZPolypharmacy and Multimorbidity in Hospitalized Patients: Clinical Consequences and Strategies for Medication Optimizationhttps://www.pharmaradar360.com/article/ramadan-fasting-and-thyroid-function-a-narrative-review-of-physiological-adaptat-7b51ac2a6f4820a9PharmaRadar360en2026-09-25T00:00:00.000ZRamadan fasting and thyroid function: a narrative review of physiological adaptation and clinical managementhttps://www.pharmaradar360.com/article/correction-to-muscle-activation-after-transtibial-amputation-clinical-and-rehabi-93679889148d9a2ePharmaRadar360en2026-09-25T00:00:00.000ZCorrection to: Muscle Activation After Transtibial Amputation: Clinical and Rehabilitation Insightshttps://www.pharmaradar360.com/article/co-delivery-of-methotrexate-and-curcumin-in-hyaluronic-acid-coated-solid-lipid-n-bdb4a64c1b090f5bPharmaRadar360en2026-09-25T00:00:00.000ZCo-delivery of methotrexate and curcumin in hyaluronic acid-coated solid lipid nanoparticles for enhanced anti-rheumatic activity in carrageenan-induced arthritishttps://www.pharmaradar360.com/article/post-traumatic-nfectious-keratitis-clinical-microbiological-and-visual-outcomes-6f786fc8dff3064fPharmaRadar360en2026-09-25T00:00:00.000ZPost-traumatic ınfectious keratitis: clinical, microbiological, and visual outcomeshttps://www.pharmaradar360.com/article/effect-of-stress-processes-induced-by-the-negative-impact-of-lead-on-rats-on-bod-96874046ebd865baPharmaRadar360en2026-09-25T00:00:00.000ZEffect of stress processes induced by the negative impact of lead on rats on body mass: determination of lead content in rat liverhttps://www.pharmaradar360.com/article/integrated-single-cell-and-spatial-transcriptomic-analysis-characterizes-a-tnbc-79a171f6ebab31aePharmaRadar360en2026-09-25T00:00:00.000ZIntegrated single-cell and spatial transcriptomic analysis characterizes a TNBC-enriched EP5-associated malignant epithelial program and prioritizes REEP4 in breast cancerhttps://www.pharmaradar360.com/article/spherical-clinical-embedding-with-adaptive-multi-expert-fusion-for-aaa-rupture-c-008c5241b71d2d7fPharmaRadar360en2026-09-25T00:00:00.000ZSpherical Clinical Embedding with Adaptive Multi-expert Fusion for AAA Rupture Classificationhttps://www.pharmaradar360.com/article/a-modality-aware-mixture-of-experts-framework-for-clinical-multimodal-breast-ult-11349169e872d62cPharmaRadar360en2026-09-25T00:00:00.000ZA Modality-Aware Mixture-of-Experts Framework for Clinical Multimodal Breast Ultrasound Diagnosishttps://www.pharmaradar360.com/article/skeletal-muscle-transcriptomic-responses-to-concurrent-training-with-polyphenols-095aa02436316a77PharmaRadar360en2026-09-25T00:00:00.000ZSkeletal Muscle Transcriptomic Responses to Concurrent Training With Polyphenols in Ageing Adults: A Randomized Trialhttps://www.pharmaradar360.com/article/cost-effectiveness-of-laser-interstitial-thermal-therapy-vs-anterior-temporal-lo-2cd784718f89ad89PharmaRadar360en2026-09-25T00:00:00.000ZCost‐effectiveness of laser interstitial thermal therapy vs. anterior temporal lobectomy for drug‐resistant mesial temporal lobe epilepsy: A decision analytic modelhttps://www.pharmaradar360.com/article/transcriptomics-driven-identification-and-engineering-of-a-novel-lactone-esteras-11778ba041bbd5caPharmaRadar360en2026-09-25T00:00:00.000ZTranscriptomics‐Driven Identification and Engineering of a Novel Lactone Esterase ( <i>Sr</i> LE) for Efficient Sophorolipid Lactonization in the Yeast <i>Starmerella riodocensis</i>https://www.pharmaradar360.com/article/ofatumumab-therapy-and-long-term-seizure-outcomes-of-patients-with-relapsing-ant-67d4ec84ce91b614PharmaRadar360en2026-09-25T00:00:00.000ZOfatumumab Therapy and Long‐Term Seizure Outcomes of Patients With Relapsing Anti‐ <scp>NMDA</scp> Receptor Encephalitishttps://www.pharmaradar360.com/article/nct07843173-peri-implantation-abstinence-and-placental-health-8df54d912a3bd404PharmaRadar360en2026-09-25T00:00:00.000ZNCT07843173: Peri-implantation Abstinence and Placental Healthhttps://www.pharmaradar360.com/article/nct07842939-pre-cannulation-ultrasound-vascular-mapping-combined-with-handgrip-e-ea6a46a39948ef03PharmaRadar360en2026-09-25T00:00:00.000ZNCT07842939: Pre-Cannulation Ultrasound Vascular Mapping Combined With Handgrip Exercise and Local Cryotherapy in Hemodialysis Patients With Difficult Cannulationhttps://www.pharmaradar360.com/article/nct07842926-acute-effects-of-capacitive-resistive-radiofrequency-therapy-in-peop-3d7db39f70958919PharmaRadar360en2026-09-25T00:00:00.000ZNCT07842926: Acute Effects of Capacitive-Resistive Radiofrequency Therapy in People With Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct07842692-serum-endocan-levels-in-colorectal-cancer-3c97efba7b080f97PharmaRadar360en2026-09-25T00:00:00.000ZNCT07842692: Serum Endocan Levels in Colorectal Cancerhttps://www.pharmaradar360.com/article/nct07842536-efficacy-of-lycium-barbarum-polysaccharide-in-dry-eye-disease-manage-22032a9cb14508aaPharmaRadar360en2026-09-25T00:00:00.000ZNCT07842536: Efficacy of Lycium Barbarum Polysaccharide in Dry Eye Disease Managementhttps://www.pharmaradar360.com/article/nct07842133-the-effect-of-progressive-muscle-relaxation-exercises-on-fatigue-dys-6511c6386c58830ePharmaRadar360en2026-09-25T00:00:00.000ZNCT07842133: The Effect of Progressive Muscle Relaxation Exercises on Fatigue, Dyspnea, and Respiratory Function in Patients With Systemic Sclerosishttps://www.pharmaradar360.com/article/nct07841730-tibial-nerve-mobilization-versus-multisensory-exercises-in-patients-79bd105296f64cb3PharmaRadar360en2026-09-25T00:00:00.000ZNCT07841730: Tibial Nerve Mobilization Versus Multisensory Exercises in Patients With Diabetic Foot Ulcerhttps://www.pharmaradar360.com/article/nct07841496-alt001-in-patients-with-ischemic-stroke-in-the-sequelae-stage-0b40791cdc142754PharmaRadar360en2026-09-25T00:00:00.000ZNCT07841496: ALT001 in Patients With Ischemic Stroke in the Sequelae Stagehttps://www.pharmaradar360.com/article/nct07840859-clinical-effectiveness-of-oxygen-releasing-oral-gel-as-an-adjunct-to-70cccd112dfa932aPharmaRadar360en2026-09-25T00:00:00.000ZNCT07840859: Clinical Effectiveness of Oxygen-Releasing Oral Gel as an Adjunct to Scaling and Root Debridement in Patients With Severe Periodontal Pockets: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/nct07840573-feasibility-and-performance-of-a-structured-video-telemedicine-progr-bcf0538a8e0b6dbbPharmaRadar360en2026-09-25T00:00:00.000ZNCT07840573: Feasibility and Performance of a Structured Video Telemedicine Program in Patients With Systemic Lupus Erythematoushttps://www.pharmaradar360.com/article/nct07840547-teleneurology-assessment-program-for-creutzfeldt-jakob-disease-bf9a3961e81bf61cPharmaRadar360en2026-09-25T00:00:00.000ZNCT07840547: Teleneurology Assessment Program for Creutzfeldt-Jakob Diseasehttps://www.pharmaradar360.com/article/nct07840508-velocity-loss-training-and-parkinson-s-disease-240b3f93fd0ca415PharmaRadar360en2026-09-25T00:00:00.000ZNCT07840508: Velocity-Loss Training and Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct07840495-the-efficacy-of-low-level-laser-therapy-lllt-as-an-adjunct-treatment-74ff0760ee9eac49PharmaRadar360en2026-09-25T00:00:00.000ZNCT07840495: The Efficacy of Low-level Laser Therapy (LLLT) as an Adjunct Treatment for Pain and Functional Outcomes in Temporomandibular Disorders (TMD)https://www.pharmaradar360.com/article/nct07840430-home-based-exercise-for-improving-health-related-quality-of-life-in-a26947c447105390PharmaRadar360en2026-09-25T00:00:00.000ZNCT07840430: Home-based Exercise for Improving Health-related Quality of Life in Systemic Sclerosishttps://www.pharmaradar360.com/article/nct07834021-body-scan-meditations-to-support-well-being-in-patients-at-antwerp-u-41375b929642b76aPharmaRadar360en2026-09-25T00:00:00.000ZNCT07834021: Body Scan Meditations to Support Well-Being in Patients at Antwerp University Hospital.https://www.pharmaradar360.com/article/nct07831317-multi-strain-probiotic-supplement-for-digestive-comfort-and-well-bei-7ca83f8b737254baPharmaRadar360en2026-09-25T00:00:00.000ZNCT07831317: Multi-strain Probiotic Supplement for Digestive Comfort and Well-being in Healthy Womenhttps://www.pharmaradar360.com/article/nct07817875-efficacy-safety-and-pharmacokinetics-of-tirzepatide-ly3298176-once-w-d01e4e31aeceef19PharmaRadar360en2026-09-25T00:00:00.000ZNCT07817875: Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)https://www.pharmaradar360.com/article/nct07769437-non-nutritive-sweeteners-in-inflammatory-bowel-disease-4a0a5f1029895664PharmaRadar360en2026-09-25T00:00:00.000ZNCT07769437: Non-nutritive Sweeteners in Inflammatory Bowel Diseasehttps://www.pharmaradar360.com/article/nct07768345-a-study-to-learn-about-revaccination-with-a-vaccine-called-rsvpref-i-454efe6eed63ee46PharmaRadar360en2026-09-25T00:00:00.000ZNCT07768345: A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adultshttps://www.pharmaradar360.com/article/nct07735104-the-first-in-human-study-of-qls2319-in-healthy-subjects-and-cancer-c-f83f611dd4c57f4fPharmaRadar360en2026-09-25T00:00:00.000ZNCT07735104: The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexiahttps://www.pharmaradar360.com/article/nct07670312-evaluation-of-xya02-in-patients-with-advanced-solid-tumors-440162864358cbefPharmaRadar360en2026-09-25T00:00:00.000ZNCT07670312: Evaluation of XYA02 in Patients With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct07626606-how-gut-health-affects-immune-responses-to-the-oral-rotavirus-vaccin-31b1b7f3e75e973fPharmaRadar360en2026-09-25T00:00:00.000ZNCT07626606: How Gut Health Affects Immune Responses to the Oral Rotavirus Vaccine in Adults in Zambiahttps://www.pharmaradar360.com/article/nct07624396-association-between-circulating-bdnf-levels-and-cardioembolic-stroke-333f5aba151f8344PharmaRadar360en2026-09-25T00:00:00.000ZNCT07624396: Association Between Circulating BDNF Levels and Cardioembolic Strokes in Patients Treated for Ischemic Strokehttps://www.pharmaradar360.com/article/nct07525206-a-study-to-access-intravenous-iv-telisotuzumab-adizutecan-in-combina-0879403a59c0aa87PharmaRadar360en2026-09-25T00:00:00.000ZNCT07525206: A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancerhttps://www.pharmaradar360.com/article/nct07524530-stem-cell-transplantation-for-participants-with-germline-runx1-assoc-f7c7537ec91ee762PharmaRadar360en2026-09-25T00:00:00.000ZNCT07524530: Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancershttps://www.pharmaradar360.com/article/nct07519772-a-clinical-study-of-mk-1045-in-people-with-non-hodgkin-lymphoma-mk-1-a50ac56f09684b1dPharmaRadar360en2026-09-25T00:00:00.000ZNCT07519772: A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)https://www.pharmaradar360.com/article/nct07377006-decision-support-tool-to-enhance-germline-genetic-testing-for-patien-5285daa9f071f049PharmaRadar360en2026-09-25T00:00:00.000ZNCT07377006: Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancerhttps://www.pharmaradar360.com/article/nct07367100-a-pivotal-study-evaluating-safety-and-effectiveness-of-adaptative-ti-92afb94a8c357747PharmaRadar360en2026-09-25T00:00:00.000ZNCT07367100: A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Strokehttps://www.pharmaradar360.com/article/nct07270666-ctdna-testing-to-inform-standard-of-care-treatment-decisions-in-peop-297379c3cf7b9251PharmaRadar360en2026-09-25T00:00:00.000ZNCT07270666: ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancerhttps://www.pharmaradar360.com/article/nct07216027-a-study-to-learn-about-study-medicine-called-pf-08049820-in-people-w-6d025df09f63a144PharmaRadar360en2026-09-25T00:00:00.000ZNCT07216027: A Study to Learn About Study Medicine Called PF-08049820 in People With Eczemahttps://www.pharmaradar360.com/article/nct07196748-a-protocol-of-icotrokinra-therapy-in-adult-and-adolescent-participan-43d2c33926f40196PharmaRadar360en2026-09-25T00:00:00.000ZNCT07196748: A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitishttps://www.pharmaradar360.com/article/nct07194070-a-study-on-hemolytic-disease-of-the-fetus-and-newborn-hdfn-through-g-9d04807a7dac3c6dPharmaRadar360en2026-09-25T00:00:00.000ZNCT07194070: A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registryhttps://www.pharmaradar360.com/article/nct07164443-a-study-of-pasritamig-with-or-without-jnj-87189401-versus-placebo-fo-5035cb4415c3afebPharmaRadar360en2026-09-25T00:00:00.000ZNCT07164443: A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)https://www.pharmaradar360.com/article/nct07106593-treatment-for-ptsd-and-tinnitus-303bc2b13d57d85aPharmaRadar360en2026-09-25T00:00:00.000ZNCT07106593: Treatment for PTSD and Tinnitushttps://www.pharmaradar360.com/article/nct06981091-a-multicenter-randomized-double-blind-placebo-controlled-parallel-gr-b76857e2f5e5b8abPharmaRadar360en2026-09-25T00:00:00.000ZNCT06981091: A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasishttps://www.pharmaradar360.com/article/nct06956118-electrical-vestibular-nerve-stimulation-vens-as-a-treatment-for-impr-dddc94e9572bd87fPharmaRadar360en2026-09-25T00:00:00.000ZNCT06956118: Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Improving Sleep in Visually Impaired Patientshttps://www.pharmaradar360.com/article/nct06801236-phase-1-study-of-ace-232-to-treat-patients-with-metastatic-castratio-95936c80f9b52ea2PharmaRadar360en2026-09-25T00:00:00.000ZNCT06801236: Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancerhttps://www.pharmaradar360.com/article/nct06667908-a-study-of-jnj-90301900-in-combination-with-chemoradiation-followed-82f1d5b6ab760f0cPharmaRadar360en2026-09-25T00:00:00.000ZNCT06667908: A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)https://www.pharmaradar360.com/article/nct06642337-nutritional-educational-program-on-therapy-in-iron-deficiency-anemia-330e71da13c23231PharmaRadar360en2026-09-25T00:00:00.000ZNCT06642337: Nutritional Educational Program On Therapy in Iron Deficiency Anemiahttps://www.pharmaradar360.com/article/nct06624163-evaluation-of-patient-coach-support-for-older-adults-with-obesity-577cdaa75b5e11bePharmaRadar360en2026-09-25T00:00:00.000ZNCT06624163: Evaluation of Patient Coach Support for Older Adults With Obesityhttps://www.pharmaradar360.com/article/nct06607003-induced-blood-stage-malaria-in-healthy-malaria-naive-adults-to-asses-7e071e53d6f06a4cPharmaRadar360en2026-09-25T00:00:00.000ZNCT06607003: Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assayshttps://www.pharmaradar360.com/article/nct06595940-genetic-analysis-of-uncommon-disease-presentations-in-non-us-populat-9a7defcdd77feca2PharmaRadar360en2026-09-25T00:00:00.000ZNCT06595940: Genetic Analysis of Uncommon Disease Presentations in Non-US Populationshttps://www.pharmaradar360.com/article/nct06459648-study-for-prevent-chronification-migraine-through-prediction-of-resp-751f651224054abfPharmaRadar360en2026-09-25T00:00:00.000ZNCT06459648: Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodieshttps://www.pharmaradar360.com/article/nct06383988-a-web-based-program-to-help-caregivers-of-lung-patients-learn-about-62002d70191a65fdPharmaRadar360en2026-09-25T00:00:00.000ZNCT06383988: A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resourceshttps://www.pharmaradar360.com/article/nct06349408-ibi3001-in-participants-with-unresectable-locally-advanced-or-metast-561bb4909064d74aPharmaRadar360en2026-09-25T00:00:00.000ZNCT06349408: IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumorshttps://www.pharmaradar360.com/article/nct06302257-pain-selective-anesthesia-for-labor-mobility-psalm-study-a-randomize-0e4dbd290ac0e7faPharmaRadar360en2026-09-25T00:00:00.000ZNCT06302257: Pain Selective Anesthesia for Labor Mobility (PSALM Study): a Randomized Controlled Trial of Combined Lidocaine - Chlorprocaine for Labor Epidural Analgesiahttps://www.pharmaradar360.com/article/nct06272747-study-of-xh-s003-in-healthy-volunteers-366ccf33e5652b3ePharmaRadar360en2026-09-25T00:00:00.000ZNCT06272747: Study of XH-S003 in Healthy Volunteershttps://www.pharmaradar360.com/article/nct06236841-a-phase-i-study-of-xh-s004-in-healthy-volunteers-bd38dbc6419120a2PharmaRadar360en2026-09-25T00:00:00.000ZNCT06236841: A Phase I Study of XH-S004 in Healthy Volunteershttps://www.pharmaradar360.com/article/nct06211764-a-study-of-tar-200-versus-intravesical-chemotherapy-in-participants-70fb428c8c501859PharmaRadar360en2026-09-25T00:00:00.000ZNCT06211764: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)https://www.pharmaradar360.com/article/nct06149559-a-study-of-rozanolixizumab-in-pediatric-study-participants-with-mode-37bfb1fcb56a93c9PharmaRadar360en2026-09-25T00:00:00.000ZNCT06149559: A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravishttps://www.pharmaradar360.com/article/nct06091865-a-study-to-compare-how-well-odronextamab-combined-with-chemotherapy-6660dc234a37eda6PharmaRadar360en2026-09-25T00:00:00.000ZNCT06091865: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphomahttps://www.pharmaradar360.com/article/nct05828069-a-study-with-tovorafenib-day101-as-a-treatment-option-for-progressiv-62c1d830acc793eaPharmaRadar360en2026-09-25T00:00:00.000ZNCT05828069: A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosishttps://www.pharmaradar360.com/article/nct05621291-a-multicenter-study-to-evaluate-next-generation-sequencing-ngs-testi-b35317055f480c6ePharmaRadar360en2026-09-25T00:00:00.000ZNCT05621291: A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...https://www.pharmaradar360.com/article/nct05132075-study-of-jdq443-in-comparison-with-docetaxel-in-participants-with-lo-5398a6b6916ab47aPharmaRadar360en2026-09-25T00:00:00.000ZNCT05132075: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct04923893-a-study-of-bortezomib-lenalidomide-and-dexamethasone-vrd-followed-by-44e427687aa6d817PharmaRadar360en2026-09-25T00:00:00.000ZNCT04923893: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therahttps://www.pharmaradar360.com/article/nct04606381-a-study-of-amivantamab-subcutaneous-sc-administration-for-the-treatm-2dd0ceee06690bd9PharmaRadar360en2026-09-25T00:00:00.000ZNCT04606381: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancieshttps://www.pharmaradar360.com/article/nct03759717-molecular-and-cellular-characterization-of-skull-base-tumors-28fe734c106cbfe0PharmaRadar360en2026-09-25T00:00:00.000ZNCT03759717: Molecular and Cellular Characterization of Skull Base Tumorshttps://www.pharmaradar360.com/article/nct03599245-this-is-an-extension-study-of-the-roche-p-trials-to-investigate-safe-de31de7344570942PharmaRadar360en2026-09-25T00:00:00.000ZNCT03599245: This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)https://www.pharmaradar360.com/article/nct03498261-a-prospective-randomized-double-blind-trial-to-assess-the-effect-of-94f75079d93aaff5PharmaRadar360en2026-09-25T00:00:00.000ZNCT03498261: A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplastyhttps://www.pharmaradar360.com/article/nct01900132-electrical-impedance-myography-natural-history-studies-inneuromuscul-4e262bdc8f5dcc6bPharmaRadar360en2026-09-25T00:00:00.000ZNCT01900132: Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteershttps://www.pharmaradar360.com/article/kobayashi-pharmaceutical-co-ltd-notice-regarding-certain-media-reports-622d9a7eca7e2127PharmaRadar360en2026-09-24T23:31:23.000ZKobayashi Pharmaceutical Co Ltd - Notice Regarding Certain Media Reportshttps://www.pharmaradar360.com/article/data-ownership-in-life-sciences-transactions-why-it-matters-more-than-ever-in-th-888286bf4bf04710PharmaRadar360en2026-09-24T23:05:04.000ZData Ownership in Life Sciences Transactions: Why It Matters More Than Ever in the Age of AIhttps://www.pharmaradar360.com/article/it-might-not-be-a-great-idea-to-buy-towa-pharmaceutical-co-ltd-tse-4553-for-its-6320b287911428d7PharmaRadar360en2026-09-24T22:55:56.000ZIt Might Not Be A Great Idea To Buy Towa Pharmaceutical Co., Ltd. (TSE:4553) For Its Next Dividendhttps://www.pharmaradar360.com/article/city-therapeutics-files-for-us-ipo-as-biotech-listings-surge-5daeb04034b53a20PharmaRadar360en2026-09-24T22:25:51.000ZCity Therapeutics files for US IPO as biotech listings surgehttps://www.pharmaradar360.com/article/richmond-biotech-company-feels-pressure-over-nih-grant-uncertainty-3d6ef6ed6b223974PharmaRadar360en2026-09-24T22:18:17.000ZRichmond biotech company feels pressure over NIH grant uncertaintyhttps://www.pharmaradar360.com/article/pharmaceutical-plastic-pots-market-to-2035-demand-accelerates-on-chronic-disease-f4a3a5c86f34ff5cPharmaRadar360en2026-09-24T22:06:04.000ZPharmaceutical Plastic Pots Market To 2035: Demand Accelerates on Chronic Disease and Self-Care Trends - News and Statisticshttps://www.pharmaradar360.com/article/cty-ipo-news-rna-interference-biotech-city-therapeutics-files-for-a-100-million-f57f26022f990fc3PharmaRadar360en2026-09-24T21:38:00.000ZCTY IPO News - RNA interference biotech City Therapeutics files for a $100 million IPOhttps://www.pharmaradar360.com/article/house-and-senate-members-propose-legislation-for-cisa-to-step-up-cyber-defenses-e612a03d10136345PharmaRadar360en2026-09-24T21:28:49.000ZHouse and Senate members propose legislation for CISA to step up cyber defenses for biotechhttps://www.pharmaradar360.com/article/australia-starts-investigation-into-openai-medicare-breach-a86a3687e693513cPharmaRadar360en2026-09-24T21:26:15.000ZAustralia starts investigation into OpenAI Medicare breachhttps://www.pharmaradar360.com/article/how-the-fda-s-new-rule-could-accelerate-non-animal-testing-in-beauty-3c553e6eaaa6ba66PharmaRadar360en2026-09-24T21:18:41.000ZHow the FDA’s New Rule Could Accelerate Non-Animal Testing in Beautyhttps://www.pharmaradar360.com/article/trump-fda-pick-dodges-vaccine-abortion-questions-at-senate-confirmation-hearing-8c24e92bad0a3ccePharmaRadar360en2026-09-24T21:14:00.000ZTrump FDA pick dodges vaccine, abortion questions at Senate confirmation hearinghttps://www.pharmaradar360.com/article/biotech-the-party-s-over-the-top-is-in-nysearca-xbi-ccd380813c56ca50PharmaRadar360en2026-09-24T20:55:11.000ZBiotech: The Party's Over, The Top Is In (NYSEARCA:XBI)https://www.pharmaradar360.com/article/richmond-biotech-company-feels-pressure-over-nih-grant-uncertainty-a16a33d04af6ae48PharmaRadar360en2026-09-24T20:47:21.000ZRichmond biotech company feels pressure over NIH grant uncertaintyhttps://www.pharmaradar360.com/article/voyager-technologies-exobiosphere-team-for-biotech-research-67960ecbc1248c01PharmaRadar360en2026-09-24T20:35:41.000ZVoyager Technologies, Exobiosphere Team For Biotech Researchhttps://www.pharmaradar360.com/article/fda-nominee-evasive-on-abortion-pill-but-firm-on-vaccine-safety-8abce6ebccf2a425PharmaRadar360en2026-09-24T20:31:23.000ZFDA nominee evasive on abortion pill but firm on vaccine safetyhttps://www.pharmaradar360.com/article/50-pro-life-leaders-call-on-fda-nominee-dr-heidi-overton-to-restore-minimal-safe-b4a6cb899b86a77ePharmaRadar360en2026-09-24T19:48:57.000Z50 pro-life leaders call on FDA nominee Dr. Heidi Overton to restore 'minimal safeguards' on mifepristonehttps://www.pharmaradar360.com/article/the-fda-s-overton-era-and-dispatches-from-shanghai-51acf1b2992e66e0PharmaRadar360en2026-09-24T19:35:29.000ZThe FDA’s Overton era, and dispatches from Shanghaihttps://www.pharmaradar360.com/article/aria-cybersecurity-announces-a-leading-pharmaceutical-manufacturer-deploys-azt-p-edd8e9566658b5e3PharmaRadar360en2026-09-24T19:15:52.000ZARIA Cybersecurity Announces a Leading Pharmaceutical Manufacturer Deploys AZT PROTECThttps://www.pharmaradar360.com/article/pro-life-groups-ask-fda-to-restore-abortion-pill-safeguards-704a0ff085fc32d2PharmaRadar360en2026-09-24T19:11:36.000ZPro-Life Groups Ask FDA To Restore Abortion Pill Safeguardshttps://www.pharmaradar360.com/article/anmat-participo-de-la-30a-reunion-del-foro-internacional-de-reguladores-de-dispo-9a67a011afc45e36PharmaRadar360en2026-09-24T19:06:50.000ZANMAT participó de la 30ª reunión del Foro Internacional de Reguladores de Dispositivos Médicoshttps://www.pharmaradar360.com/article/exclusive-sen-hawley-says-fda-commissioner-nominee-denied-dangers-of-chemical-ab-1161e11edbe13322PharmaRadar360en2026-09-24T19:06:17.000ZEXCLUSIVE: Sen. Hawley says FDA commissioner nominee denied dangers of chemical abortion; demands answers amid lawsuits, official reviewhttps://www.pharmaradar360.com/article/fda-slams-glp-1-compounder-over-risk-of-contaminating-drugs-with-filth-8bcdf3d618446ae8PharmaRadar360en2026-09-24T18:58:54.000ZFDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’https://www.pharmaradar360.com/article/governor-hochul-celebrates-completion-of-ima-life-north-america-s-30-million-exp-0ef7bfd615ba30f2PharmaRadar360en2026-09-24T18:54:41.000ZGovernor Hochul Celebrates Completion of IMA Life North America’s $30 Million Expansion Project in Tonawandahttps://www.pharmaradar360.com/article/dr-heidi-overton-appears-before-senate-committee-for-confirmation-hearing-as-nex-927f5ad766e1ef04PharmaRadar360en2026-09-24T18:34:27.000ZDr. Heidi Overton appears before Senate committee for confirmation hearing as next FDA commissionerhttps://www.pharmaradar360.com/article/trump-s-fda-pick-heidi-overton-calls-vaccines-mifepristone-safe-and-effective-in-7432ec419d7fa40ePharmaRadar360en2026-09-24T18:32:51.000ZTrump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearinghttps://www.pharmaradar360.com/article/copeland-closes-dickson-deal-to-expand-cold-chain-monitoring-9e5f8bef77b45a28PharmaRadar360en2026-09-24T18:29:27.000ZCopeland Closes Dickson Deal to Expand Cold Chain Monitoringhttps://www.pharmaradar360.com/article/fda-nominee-overton-says-all-us-vaccines-safe-as-senators-press-on-shots-abortio-9d53ed4780db055ePharmaRadar360en2026-09-24T18:23:17.000ZFDA nominee Overton says all US vaccines safe as senators press on shots, abortion, vapinghttps://www.pharmaradar360.com/article/targeted-therapy-may-improve-function-survival-in-fus-als-7f66b0be01dbe142PharmaRadar360en2026-09-24T18:13:56.000ZTargeted therapy may improve function, survival in FUS-ALShttps://www.pharmaradar360.com/article/fda-approves-onswik-pharmexec-a912f4b5c9411f64PharmaRadar360en2026-09-24T17:57:03.000ZFDA Approves Onswik | PharmExechttps://www.pharmaradar360.com/article/why-is-acadia-pharmaceuticals-stock-tumbling-today-acadia-pharmaceuticals-nasdaq-cdfa7fc397f2f998PharmaRadar360en2026-09-24T17:43:33.000ZWhy Is Acadia Pharmaceuticals Stock Tumbling Today? - ACADIA Pharmaceuticals (NASDAQ:ACAD)https://www.pharmaradar360.com/article/kyverna-s-cell-therapy-shows-lasting-autoimmune-benefit-2450aa478dccce91PharmaRadar360en2026-09-24T17:35:20.000ZKyverna’s cell therapy shows lasting autoimmune benefithttps://www.pharmaradar360.com/article/positive-fda-alignment-boosts-atyr-pharma-s-rare-lung-disease-09bca1f5840f8f0dPharmaRadar360en2026-09-24T17:31:27.000ZPositive FDA Alignment Boosts ATyr Pharma's Rare Lung Diseasehttps://www.pharmaradar360.com/article/fda-nominee-pressed-on-vaccines-abortion-pill-e773458488d78778PharmaRadar360en2026-09-24T17:31:21.000ZFDA Nominee Pressed on Vaccines, Abortion Pill